Quantum BioPharma Addresses Misinformation Regarding Unbuzzd Wellness and Clarifies Stock Trading Platform Errors

Quantum BioPharma (QNTM) clarified that it has not changed its name to Unbuzzd Wellness Inc. and is not undergoing a reverse takeover. Quantum BioPharma maintains a significant financial relationship with Unbuzzd, including a 7% royalty on Unbuzzd revenue until $250 million is reached, and retains a substantial equity stake with anti-dilution protection. The company also announced a debt settlement plan with certain vendors, issuing Class B shares for vendor payments.

Analysis

Quantum BioPharma Ltd. (NASDAQ: QNTM) has proactively addressed market confusion by unequivocally stating it has not changed its name and is not involved in a reverse takeover transaction with Unbuzzd Wellness Inc. This clarification aims to stabilize investor perception amidst misinformation. Quantum BioPharma maintains a significant strategic and financial interest in Unbuzzd, being its largest shareholder and debt holder. This includes a lucrative royalty agreement granting Quantum 7% of Unbuzzd's revenue until $250 million is paid, then reducing to 3%, and ownership of 200,000,000 post-split common shares in Unbuzzd, with an anti-dilution warrant ensuring at least a 25% stake upon a go-public event. Furthermore, Quantum has extended a $1.3 million secured loan to Unbuzzd at 10% annual interest. Unbuzzd is strengthening its position for a potential IPO by engaging MNP LLP for PCAOB audits, a move signaling robust governance and preparation for public markets. The leadership at Unbuzzd, including CEO John Duffy (ex-Coca-Cola) and Board Co-Chair Gerry David (former CEO of Celsius Holdings), adds significant industry experience, potentially enhancing Unbuzzd's market penetration with its scientifically-backed alcohol metabolism aid. Concurrently, Quantum BioPharma announced a debt settlement of USD$20,930 with vendors through the issuance of Class B Shares, which, while resolving obligations, may indicate current cash flow pressures. The company's core biopharmaceutical focus includes Lucid-MS for multiple sclerosis, while Unbuzzd represents a commercialized OTC asset.

Key Decisions for Investors

• Investors should monitor Unbuzzd Wellness Inc.'s progress towards its potential IPO and the market adoption of its unbuzzd™ product, as these are key catalysts for Quantum BioPharma's royalty revenue and equity value.
• Consider the dual nature of Quantum BioPharma's strategy: its core biopharmaceutical development (e.g., Lucid-MS) alongside its significant financial leverage to Unbuzzd's success, assessing the risk-reward profile of this diversified approach.
• Scrutinize Quantum BioPharma's balance sheet and cash flow statements in future reports, particularly in light of the recent debt settlement via share issuance, to gauge its financial resilience independent of Unbuzzd's performance.
• Evaluate the long-term implications of the anti-dilution warrant and royalty structure with Unbuzzd, which offers substantial upside but also ties a significant portion of Quantum's future value to Unbuzzd's market execution.